Azenta (AZTA) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue rose 4% year-over-year to $173 million, with 5% organic growth driven by Sample Management Solutions and B Medical Systems, while Multiomics remained flat.

• Adjusted EBITDA nearly doubled year-over-year to $18 million, with margin expanding to 10.3%, and non-GAAP EPS was $0.16.

• Transformation initiatives (Ascend 2026) delivered cost savings, site optimizations, and portfolio focus, supporting margin expansion and operational improvements.

• Returned to profitability on an adjusted basis, but reported a net loss of $6.6 million due to lower interest income and significant non-cash impairment charges.

• The company realigned into three segments: Sample Management Solutions, Multiomics, and B Medical Systems, effective October 1, 2023.

Financial highlights

• Q3 revenue reached $173 million, up 4% year-over-year reported and 5% organic; all segments grew.

• Adjusted EBITDA margin was 10.3%, expanding 260 basis points year-over-year and 440 basis points sequentially.

• Non-GAAP EPS was $0.16; non-GAAP gross margin was 45.2%, down 40 basis points year-over-year due to prior-year non-recurring items.

• Ended quarter with $754 million in cash, cash equivalents, and marketable securities; no debt.

• Returned $225.9 million to shareholders via repurchase of 4.2 million shares in Q3; $1.3 billion of $1.5 billion buyback program completed.

Outlook and guidance

• Full-year revenue guidance lowered to $652–$658 million (down 2% to down 1%), reflecting B Medical conversion delays and OEM order shifts.

• Adjusted EBITDA margin expansion of ~300 basis points for FY24 reaffirmed; non-GAAP EPS guide raised to $0.30–$0.36.

• Interest income for FY24 expected to be ~$32 million; tax rate expected at 30%–34%.

• Management expects current cash and equivalents to fund operations and capital needs for at least one year and the foreseeable future.

• Transformation initiatives and cost reduction efforts to continue through fiscal 2026.